210 related articles for article (PubMed ID: 20228131)
1. Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.
Lehmann-Che J; André F; Desmedt C; Mazouni C; Giacchetti S; Turpin E; Espié M; Plassa LF; Marty M; Bertheau P; Sotiriou C; Piccart M; Symmans WF; Pusztai L; de Thé H
Oncologist; 2010; 15(3):246-52. PubMed ID: 20228131
[TBL] [Abstract][Full Text] [Related]
2. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
[TBL] [Abstract][Full Text] [Related]
3. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
Bertheau P; Turpin E; Rickman DS; Espié M; de Reyniès A; Feugeas JP; Plassa LF; Soliman H; Varna M; de Roquancourt A; Lehmann-Che J; Beuzard Y; Marty M; Misset JL; Janin A; de Thé H
PLoS Med; 2007 Mar; 4(3):e90. PubMed ID: 17388661
[TBL] [Abstract][Full Text] [Related]
4. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
Di Leo A; Gancberg D; Larsimont D; Tanner M; Jarvinen T; Rouas G; Dolci S; Leroy JY; Paesmans M; Isola J; Piccart MJ
Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526
[TBL] [Abstract][Full Text] [Related]
5. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.
Kariya S; Ogawa Y; Nishioka A; Moriki T; Ohnishi T; Ito S; Murata Y; Yoshida S
Radiat Med; 2005 May; 23(3):189-94. PubMed ID: 15940066
[TBL] [Abstract][Full Text] [Related]
6. p53 as a specific prognostic factor in triple-negative breast cancer.
Chae BJ; Bae JS; Lee A; Park WC; Seo YJ; Song BJ; Kim JS; Jung SS
Jpn J Clin Oncol; 2009 Apr; 39(4):217-24. PubMed ID: 19304743
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting.
Petit T; Borel C; Ghnassia JP; Rodier JF; Escande A; Mors R; Haegelé P
Clin Cancer Res; 2001 Jun; 7(6):1577-81. PubMed ID: 11410493
[TBL] [Abstract][Full Text] [Related]
8. Impact of tumor biology, particularly triple-negative status, on response to pre-operative sequential, dose-dense epirubicin, cyclophosphamide followed by docetaxel in breast cancer.
Warm M; Kates R; Grosse-Onnebrink E; Stoff-Khalili M; Hoopmann M; Mallmann P; Thomas A; Harbeck N
Anticancer Res; 2010 Oct; 30(10):4251-9. PubMed ID: 21036749
[TBL] [Abstract][Full Text] [Related]
9. Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers.
Naoi Y; Kishi K; Tanei T; Tsunashima R; Tominaga N; Baba Y; Kim SJ; Taguchi T; Tamaki Y; Noguchi S
Cancer; 2011 Aug; 117(16):3682-90. PubMed ID: 21305539
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity.
Bozzetti C; Musolino A; Camisa R; Bisagni G; Flora M; Bassano C; Martella E; Lagrasta C; Nizzoli R; Personeni N; Leonardi F; Cocconi G; Ardizzoni A
Am J Clin Oncol; 2006 Apr; 29(2):171-7. PubMed ID: 16601438
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
[TBL] [Abstract][Full Text] [Related]
12. Predictive biological markers for response of invasive breast cancer to anthracycline/cyclophosphamide-based primary (radio-)chemotherapy.
Prisack HB; Karreman C; Modlich O; Audretsch W; Danae M; Rezai M; Bojar H
Anticancer Res; 2005; 25(6C):4615-21. PubMed ID: 16334152
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
14. 14-3-3σ expression is associated with poor pathological complete response to neoadjuvant chemotherapy in human breast cancers.
Nakamura Y; Oshima K; Naoi Y; Nakayama T; Kim SJ; Shimazu K; Shimomura A; Maruyama N; Tamaki Y; Noguchi S
Breast Cancer Res Treat; 2012 Jul; 134(1):229-36. PubMed ID: 22315133
[TBL] [Abstract][Full Text] [Related]
15. Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy.
Martin-Richard M; Muñoz M; Albanell J; Colomo L; Bellet M; Rey MJ; Tabernero J; Alonso C; Cardesa A; Gascon P; Fernandez PL
Oncology; 2004; 66(5):388-94. PubMed ID: 15331926
[TBL] [Abstract][Full Text] [Related]
16. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
17. Prediction of response to repeat utilization of anthracycline in recurrent breast cancer patients previously administered anthracycline-containing chemotherapeutic regimens as neoadjuvant or adjuvant chemotherapy.
Yonemori K; Katsumata N; Kaneko M; Uno H; Matsumoto K; Kouno T; Shimizu C; Ando M; Takeuchi M; Fujiwara Y
Breast Cancer Res Treat; 2007 Jul; 103(3):313-8. PubMed ID: 17063267
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
19. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.
Muss HB; Thor AD; Berry DA; Kute T; Liu ET; Koerner F; Cirrincione CT; Budman DR; Wood WC; Barcos M
N Engl J Med; 1994 May; 330(18):1260-6. PubMed ID: 7908410
[TBL] [Abstract][Full Text] [Related]
20. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L
Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
